Vivos Therapeutics Strengthens Leadership to Drive Future Growth
Vivos Therapeutics Enhances Management Team for Strategic Growth
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering medical technology firm focused on innovative treatments for obstructive sleep apnea (OSA) and snoring, recently bolstered its management team by appointing two key leaders. Michael (Mike) E. Bruhn has taken on the role of Executive Vice President of Business Operations Integration, while Dr. Terry Jones steps into the position of Senior Vice President of Human Resources.
Commitment to Expansion
These strategic appointments underscore Vivos' commitment to executing its innovative business model. The company is currently experiencing a transformative phase following its acquisition of The Sleep Center of Nevada. This acquisition, along with ongoing evaluations of additional collaborative opportunities, showcases Vivos' plans to enhance scalability and expand revenue streams.
Drawing Expertise to Tackle OSA
Both Mr. Bruhn and Dr. Jones were attracted to Vivos by its mission to eliminate OSA, a condition that remains significantly underdiagnosed and under-treated despite affecting millions. They will report directly to R. Kirk Huntsman, the Chairman and CEO of Vivos, as they embark on initiatives aimed at furthering the company's reach and efficacy in addressing sleep disorders.
Mr. Bruhn's New Role and Focus
In his new position, Mr. Bruhn is tasked with spearheading Vivos' operational expansion, especially in the Eastern United States. His responsibilities will include facilitating the integration of both existing and newly acquired entities into Vivos' operational framework. With a keen eye on scalable growth and operational efficiency, Mr. Bruhn aims to support accessibility to Vivos' innovative OSA solutions for patients nationwide. He will collaborate closely with Susan McCullough, the Executive Vice President of Operations and Co-Founder of Vivos, ensuring seamless practical implementation of their proprietary treatments within dental and medical practices.
Mr. Bruhn's Impressive Background
Before joining Vivos, Mr. Bruhn held numerous significant positions, including Executive Vice President and Chief Operating Officer at the U.S. Institute of Peace (USIP). His extensive background includes leading healthcare consulting initiatives at IQVIA Holdings, where he supported multiple governmental health agencies over several years. Moreover, he possesses over two decades of service in the U.S. Air Force Medical Service, climbing to the rank of colonel while holding various senior leadership roles.
Dr. Jones’ Vision for HR
Dr. Jones brings a wealth of experience to Vivos, having served in the role of Vice President of Human Resources at USIP. His educational background features a Doctorate in Management, an MBA in Human Resources Management, and a Bachelor of Science in Business. Dr. Jones is poised to lead Vivos' HR strategies, fostering a culture that prioritizes employee engagement and development. His extensive expertise in leading large workforces internationally positions him well to implement transformational HR strategies that will cultivate a motivated and high-performing work environment at Vivos.
A Focus on Collaborative Growth
As both leaders immerse themselves in their new roles, Vivos anticipates significant organizational benefits. Their combined focus on operational and human resource strategies is expected to yield a thriving workplace that supports the ongoing mission of improving patient wellness. Both Mr. Bruhn and Dr. Jones aim to enhance Vivos’ capabilities to integrate acquired entities efficiently, facilitating a conducive environment for growth and innovation in treatments for sleep apnea.
About Vivos Therapeutics
Founded in 2016, Vivos Therapeutics, Inc. (NASDAQ: VVOS) is focused on developing and commercializing groundbreaking diagnostic and treatment solutions for patients suffering from breathing and sleep disorders such as obstructive sleep apnea (OSA). Vivos' Complete Airway Repositioning and/or Expansion (CARE) devices stand as the only FDA-cleared oral appliances capable of treating adult patients suffering from all severity levels of OSA, including children aged six to 17 with moderate-to-severe OSA.
The Challenge of OSA
Obstructive sleep apnea is a global health crisis affecting over a billion individuals, with 90% unaware of their condition. The potential health consequences of untreated OSA link it to numerous chronic diseases. Addressing these effectively requires not just medical advances but a holistic understanding of patient needs and challenges. Vivos is committed to pioneering solutions that effectively tackle the core issues associated with OSA.
Innovative Technology and Collaborations
Vivos is changing the landscape for sleep wellness through advanced technologies and initiatives that involve collaborations with functional medicine experts and sleep specialists. By empowering healthcare providers, Vivos aims to address the needs of patients in a more comprehensive and efficient manner, providing the hope for improved health and well-being.
Frequently Asked Questions
What are the recent changes in Vivos Therapeutics management?
Vivos has appointed Michael E. Bruhn as Executive Vice President and Dr. Terry Jones as Senior Vice President to support its growth and operational integration.
What is Vivos’ focus following these new appointments?
The company aims to enhance its operations and expand its acquisition strategy to tackle obstructive sleep apnea more effectively.
How does Vivos plan to improve patient care?
Vivos is focused on integrating new acquisitions, scaling operations efficiently, and enhancing access to its OSA solutions for broader patient demographics.
What experience do the new executives bring to Vivos?
Both executives come with extensive backgrounds in leadership, operations, and human resources, with significant experience in healthcare and related sectors.
Why is recognizing OSA important for public health?
Obstructive sleep apnea affects millions and can lead to serious health issues if untreated, making effective diagnosis and treatment crucial for overall public health.
About The Author
Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.